A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on ventana's platform

Journal of Thoracic Oncology

Volumn 11, Issue 11, 2016, Pages 1863-1868

  Neuman, Tzahi ^a   London, Michal ^b   Kania Almog, Juliane ^c,d   Litvin, Anna ^c   Zohar, Yaniv ^e   Fridel, Ludmila ^d,f   Sandbank, Judith ^d,g   Barshak, Iris ^d,h   Vainer, Gilad W ^c,d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Gamidor Diagnostics Inc   (Israel)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

^f RABIN MEDICAL CENTER   (Israel)

^g ASSAF HAROFEH MEDICAL CENTER   (Israel)

^h SHEBA MEDICAL CENTER   (Israel)

Author keywords

Dako; Harmonization; IHC; PD L1; Ventana

Indexed keywords

PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; TONSIL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; IMMUNOLOGY; LUNG NEOPLASMS; PROCEDURES; REPRODUCIBILITY; STAINING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING;

EID: 84995903906     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.08.146     Document Type: Article

References (7)

1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
2. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
3. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
4. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540-1550.
5. US Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health Center for Biologics Evaluation and Research Center for Drug Evaluation and Research. Guidance for Food and Drug Administration Staff. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf. Acccessed May 1, 2016.
6. Philip R, Carrington L, Chan M. US FDA perspective on challenges in co-developing in vitro companion di- A gnostics and targeted cancer therapeutics. Bioanalysis. 2011;3:383-389.
7. Yu H, Boyle TA, Zhou C, et al. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11:964-975.